Faron Pharmaceuticals Oy (FARN.L)
GBp 175.0
(2.94%)
GBp 175.0
(2.94%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -28.56 Million EUR | -4.16% |
| 2022 | -27.42 Million EUR | -29.93% |
| 2021 | -21.1 Million EUR | -26.74% |
| 2020 | -16.65 Million EUR | -27.12% |
| 2019 | -13.1 Million EUR | 34.46% |
| 2018 | -19.98 Million EUR | 3.24% |
| 2017 | -20.65 Million EUR | -133.22% |
| 2016 | -8.85 Million EUR | -51.81% |
| 2015 | -5.83 Million EUR | -375.16% |
| 2014 | -1.22 Million EUR | 0.97% |
| 2013 | -1.24 Million EUR | 47.32% |
| 2012 | -2.35 Million EUR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -5645.00 EUR | 0.0% |
| 2024 Q1 | -5645.00 EUR | 28.34% |
| 2023 Q3 | -7878.00 EUR | -22.98% |
| 2023 Q4 | -7878.00 EUR | 0.0% |
| 2023 FY | -28.56 Million EUR | -4.16% |
| 2023 Q1 | -6406.00 EUR | 8.89% |
| 2023 Q2 | -6406.00 EUR | 0.0% |
| 2022 Q3 | -7031.00 EUR | -5.23% |
| 2022 Q4 | -7031.00 EUR | 0.0% |
| 2022 FY | -27.42 Million EUR | -29.93% |
| 2022 Q1 | -6681.50 EUR | -25.07% |
| 2022 Q2 | -6681.50 EUR | 0.0% |
| 2021 Q2 | -5212.00 EUR | 0.0% |
| 2021 Q4 | -5342.00 EUR | 0.0% |
| 2021 Q3 | -5342.00 EUR | -2.49% |
| 2021 FY | -21.1 Million EUR | -26.74% |
| 2021 Q1 | -5212.00 EUR | -9.62% |
| 2020 Q2 | -3572.50 EUR | 0.0% |
| 2020 Q1 | -3572.50 EUR | -5.73% |
| 2020 Q3 | -4754.50 EUR | -33.09% |
| 2020 FY | -16.65 Million EUR | -27.12% |
| 2020 Q4 | -4754.50 EUR | 0.0% |
| 2019 FY | -13.1 Million EUR | 34.46% |
| 2019 Q1 | -3171.50 EUR | -6.61% |
| 2019 Q2 | -3171.50 EUR | 0.0% |
| 2019 Q3 | -3379.00 EUR | -6.54% |
| 2019 Q4 | -3379.00 EUR | 0.0% |
| 2018 FY | -19.98 Million EUR | 3.24% |
| 2018 Q4 | -2975.00 EUR | 0.0% |
| 2018 Q3 | -2975.00 EUR | 57.62% |
| 2018 Q2 | -7019.50 EUR | 0.0% |
| 2018 Q1 | -7019.50 EUR | -1.56% |
| 2017 Q1 | -3418.00 EUR | -8.15% |
| 2017 Q2 | -3418.00 EUR | 0.0% |
| 2017 FY | -20.65 Million EUR | -133.22% |
| 2017 Q4 | -6911.50 EUR | 0.0% |
| 2017 Q3 | -6911.50 EUR | -102.21% |
| 2016 Q2 | -1691.00 EUR | 0.0% |
| 2016 Q4 | -3160.50 EUR | 0.0% |
| 2016 FY | -8.85 Million EUR | -51.81% |
| 2016 Q3 | -3160.50 EUR | -86.9% |
| 2016 Q1 | -1691.00 EUR | 2.96% |
| 2015 FY | -5.83 Million EUR | -375.16% |
| 2015 Q3 | -1742.50 EUR | -48.23% |
| 2015 Q4 | -1742.50 EUR | 0.0% |
| 2015 Q1 | -1175.50 EUR | -276.76% |
| 2015 Q2 | -1175.50 EUR | 0.0% |
| 2014 Q3 | -312.00 EUR | -3.31% |
| 2014 Q1 | -302.00 EUR | 0.0% |
| 2014 FY | -1.22 Million EUR | 0.97% |
| 2014 Q4 | -312.00 EUR | 0.0% |
| 2014 Q2 | -302.00 EUR | 0.0% |
| 2013 FY | -1.24 Million EUR | 47.32% |
| 2012 FY | -2.35 Million EUR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|